Mirum (MIRM) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $176.2M
- Gross margin
- 81.72%
- Net income (quarter)
- −$67.2M
- Net income growth (year over year)
- −1047.02%
- Net margin
- −139.18%
- Return on equity
- −702.97%
- EPS (trailing twelve months)
- −$14.08
- Book value per share
- −$0.16
- Debt to assets
- 101.00%
Company profile
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Frequently asked questions
Is Mirum (MIRM) profitable?
No. Mirum reported a net loss of $860.2M over the trailing twelve months.
How much revenue does Mirum (MIRM) make?
Mirum generated $618.1M in revenue over the trailing twelve months, up 37.92% year over year.
How do I buy stock in Mirum (MIRM)?
MIRM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.